Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine

Equality Impact Assessment (Guidance development) (PDF 156 KB)

Appeal

Ipsen : Appeal letter (MSWord 312 KB)

Ipsen : Scrutiny letter (MSWord 77 KB)

Ipsen : Response to scrutiny letter (MSWord 83 KB)

Ipsen : Final scrutiny letter (MSWord 66 KB)

Appeal decision (MSWord 47 KB)

Final draft guidance

Final draft guidance (PDF 287 KB)

Committee papers (PDF 1.99 MB)

Public committee slides (PDF 530 KB)

Final draft guidance Equality Impact Assessment (PDF 156 KB)

Draft guidance

Appraisal consultation document (PDF version) (PDF 301 KB)

Public committee slides (PDF 907 KB)

Committee papers (PDF 9.13 MB)

Appraisal consultation document (online commenting)

Committee meeting: 2

Supporting documentation Register of Interests (PDF 137 KB)

Equality impact assessment (Scoping) (PDF 125 KB)

Final scope (PDF 171 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 255 KB)

Final stakeholder list (PDF 164 KB)

Draft scope post referral (PDF 176 KB)

Draft matrix post referral (PDF 162 KB)